UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 頭頸部癌の初期治療中の合併症のマネージメントおよび予防 management and prevention of complications during initial treatment of head and neck cancer
2. シスプラチン腎障害 cisplatin nephrotoxicity
3. 放射線療法誘発性肺障害 radiation induced lung injury
4. 放射線誘発性線維症の臨床症状および治療 clinical manifestations and treatment of radiation induced fibrosis
5. 癌患者における膀胱炎 cystitis in patients with cancer

English Journal

Raman spectroscopy demonstrates Amifostine induced preservation of bone mineralization patterns in the irradiated murine mandible.

Tchanque-Fossuo CN, Gong B, Poushanchi B, Donneys A, Sarhaddi D, Gallagher KK, Deshpande SS, Goldstein SA, Morris MD, Buchman SR.SourceUniversity of Michigan Hospital and Health Systems, Pediatric Plastic Surgery Section, 1540 E. Hospital Drive, MI 48109, USA.
Bone.Bone.2013 Feb;52(2):712-7. doi: 10.1016/j.bone.2012.07.029. Epub 2012 Aug 3.
PURPOSE: Adjuvant radiotherapy in the management of head and neck cancer remains severely debilitating. Fortunately, newly developed agents aimed at decreasing radiation-induced damage have shown great promise. Amifostine (AMF) is a compound, which confers radio-protection to the exposed normal tiss
PMID 22885239

Postmastectomy Hypofractionated and Accelerated Radiation Therapy With (and Without) Subcutaneous Amifostine Cytoprotection.

Koukourakis MI, Panteliadou M, Abatzoglou IM, Sismanidou K, Sivridis E, Giatromanolaki A.SourceDepartment of Radiotherapy/Oncology, Democritus University of Thrace, Alexandroupolis, Greece. Electronic address: targ@her.forthnet.gr.
International journal of radiation oncology, biology, physics.Int J Radiat Oncol Biol Phys.2013 Jan 1;85(1):e7-e13. doi: 10.1016/j.ijrobp.2012.08.017. Epub 2012 Oct 3.
PURPOSE: Postmastectomy radiation therapy (PMRT) provides major local control and survival benefits. More aggressive radiation therapy schemes may, however, be necessary in specific subgroups, provided they are safely administered. We report the tolerance and efficacy of a highly accelerated and hyp
PMID 23040218

Systematic review of amifostine for the management of oral mucositis in cancer patients.

Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, Riesenbeck D, Stokman M, Tissing W, Yeoh E, Elad S, Lalla RV; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).SourceDental Oncology Unit, Clinic of Hospital Dentistry, Dental School, University of Athens, Athens, Greece. nicolatou.galitis@hotmail.com
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.Support Care Cancer.2013 Jan;21(1):357-64. doi: 10.1007/s00520-012-1613-6. Epub 2012 Oct 3.
PURPOSE: The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients.METHODS: A systematic review was conducted by the Mucositis
PMID 23052919

Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model

Cardioprotection of rat heart myocytes with amifostine (ethyol) and its free thiol, WR-1065, in vitro

ethyol logo Natfost - Ethyol (Amifostine) 500 MG Ethyol rebrand Last Updated: 3/4/2014 Ethyol-Generic, Amifostine 10ml. Ethyol Ethyol

リンク元

アミホスチン : 約 2,740 件
アミフォスチン : 約 2,130 件